HB 5127 regulates how health care providers and veterinary care providers may market, discuss, and use third-party financing for patient and client purchases. Beginning January 1, 2027, providers are prohibited from advertising or promoting third-party financing in certain ways, including using their branding on financing signage, directing consumers to branded financing websites or QR codes, discussing financing while a patient is under anesthesia or while treatment is being provided, or doing so in treatment areas. Providers also may not receive incentives for promoting financing, complete or submit financing applications on a consumer’s behalf, or charge financing accounts for services before the service is provided, subject to limited exceptions.
The bill also requires a written disclosure when a provider discusses the terms and conditions of third-party financing. The disclosure explains that the financing is a credit card, line of credit, or loan from a third-party lender, not a provider payment plan, and warns consumers about interest, penalties, credit reporting, and collection risks. Providers are not required to give the disclosure if they merely state that third-party financing is accepted without discussing its terms.
In addition, if ancillary products are purchased through third-party financing, the provider must allow a 30-day return and issue a full refund, unless the product is customized or has been used, damaged, tampered with, or improperly stored. The bill preserves preexisting agreements entered into before January 1, 2027, and makes violations unfair or deceptive trade practices enforceable solely by the Attorney General, rather than through private actions under the consumer protection statute.
The bill’s impact is to add a new layer of consumer-protection regulation to health care and veterinary billing practices, affecting providers, patients, pet owners, and third-party lenders or financing vendors. It does not ban financing, but it sharply limits provider involvement in promoting or administering it and imposes disclosure and refund obligations tied to financing-related sales.
Overall sentiment appears strongly favorable, as reflected by the large bipartisan vote margins in committee, the House, and the Senate. The main point of contention is the degree of restriction on provider participation in financing arrangements, especially whether the bill goes too far in limiting how providers can help patients or clients access credit. Another potential concern is enforcement, since the bill channels violations exclusively to the Attorney General and removes private enforcement under the usual unfair trade practice remedy.
The bill creates a new statutory framework effective January 1, 2027, governing third-party financing in the context of health care and veterinary services. It defines key terms such as health care provider, veterinary care provider, ancillary product, and third-party financing, then imposes restrictions on marketing, application assistance, timing of charges, disclosures, and refund rights. It also amends the enforcement landscape by classifying violations as unfair or deceptive trade practices enforceable solely by the Attorney General, while preserving agreements made before the effective date.
The voting history suggests broad support for the bill, with strong favorable margins in committee, the House, and the Senate. The overall tone of the legislation is consumer-protective and aimed at preventing confusion or pressure around financing offers in medical and veterinary settings. Any opposition appears limited and likely centered on the operational burden for providers and the limits placed on financing-related assistance.
The main contention is between consumer protection and provider flexibility. Supporters appear to favor clearer disclosures, limits on in-room or during-treatment financing pitches, and protections against unauthorized charges or bundled ancillary-product financing. Potential critics may object that the bill restricts providers from helping patients access financing, complicates office workflows, and could interfere with legitimate payment arrangements. The exclusive Attorney General enforcement provision may also be a point of debate because it removes private rights of action while concentrating enforcement authority in the state.